Skip to content

NAD+ IV vs Injection vs Oral: Which Delivery Works Best?

Compare NAD+ IV, home injections and oral precursors by evidence, cost and practicality. Direct delivery does not establish better routine wellness results.

By Marcus HaleLongevity Research Editor
Updated

7 min read · 10 sources

On this page

If you've decided you want to raise your NAD+, the next question the wellness industry pushes hard is how: an intravenous drip, a subcutaneous injection you do at home, or oral capsules and powders. The pitch for the pricier routes leans on a single argument — bioavailability. IV "delivers 100%," injections "bypass the gut," and oral is dismissed as "only 5–15% absorbed." That slogan is not a measured head-to-head ranking for these different NAD-related compounds. But the more important fact, the one the marketing buries, is that higher blood NAD+ has not been shown to produce better health outcomes — so the route that wins on bioavailability does not automatically win on value. This guide compares the three honestly.

A provider offering several forms does not establish that their benefits are equivalent. PlexusDx prices injection, nasal spray and Flex Dose Tablet on one commitment ladder; that simplifies the bill while leaving the route-specific evidence question open.

For home shots, flexibility can also have a price: Levers Health’s one-time NAD+ purchase costs more than its one-month subscription. The choice is about purchase terms, not a demonstrated change in effectiveness.

EverPrime offers both injection and nasal NAD+, with separate medication and optional membership charges. Compare the complete bill as well as the route; a shared provider does not establish equivalent benefits.

What direct delivery does — and does not — establish

An intravenous infusion places its contents into the bloodstream, while a subcutaneous injection first passes through tissue and oral compounds undergo absorption and metabolism. Those differences do not establish a quantitative ranking for intact NAD+ reaching cells. Oral NR and NMN are also different compounds from infused NAD+, so a single percentage comparison can mislead.

Routes at a glance

Swipe table to compare all columns →

RouteBioavailability (theory)CostHuman evidence
Oral (caps/powder)Lower (first-pass)~$20–$40/moTrials show it raises NAD+
Subcutaneous injectionBypasses digestionClinic/self-pricedSparse data; wellness benefit unproven
IV infusionDirect to blood$250–$1,500/sessionMetabolism + tolerability pilots; wellness benefit unproven
Delivery into blood is not proof of better outcomes. Oral precursor trials and IV pilots answer different questions.

Two things complicate that tidy picture for NAD+ specifically, though — and they matter a lot.

First, NAD+ itself is not well-behaved when infused. A 2019 pilot tracking plasma and urine metabolites during a six-hour infusion found no significant plasma NAD+ rise in the first two hours 1. So even the "100% bioavailable" route does not simply flood your blood with intact NAD+ the way the slogan implies. A 2026 retrospective NAD+ versus NR infusion pilot adds short-term tolerability and exploratory biomarker data, but does not establish routine wellness benefits 9.

Second, the oral route clearly works at the biomarker level. The "oral barely absorbs" claim is overstated for NAD+ precursors. Oral NMN reliably raises blood NAD+ in a dose-dependent way in randomized trials 2, and multiple human studies confirm oral NMN is absorbed and efficiently increases blood NAD+ 56; oral nicotinamide riboside does the same in healthy older adults 3. So whatever the theoretical absorption percentage, the oral route demonstrably hits the target it's supposed to hit. We compare the precursors directly in NMN vs NR and the oral formats in sublingual NMN vs capsules.

The catch that flips the whole comparison

Here is the pivot the bioavailability sales pitch depends on you missing: raising blood NAD+ is not the same as improving an outcome. A route can be more bioavailable and still buy you nothing extra if the bottleneck isn't how much NAD+ reaches your blood.

And that's exactly what the outcome trials suggest. Nicotinamide riboside augmented the aged-muscle NAD+ metabolome without improving muscle performance 4. It raised NAD+ roughly 2.6-fold without improving cognition in older adults with mild cognitive impairment 7. A systematic review and meta-analysis found benefits on metabolic-syndrome parameters limited and inconsistent despite reliably higher NAD+ 8. If raising NAD+ via the well-absorbed oral route repeatedly fails to move the outcomes people care about, then choosing a more bioavailable route to raise NAD+ even higher is solving the wrong problem. More of an input that didn't deliver isn't a better deal — it's a more expensive version of the same uncertainty.

The thing the pitch omits

More bioavailable ≠ better outcomes

  • A direct route into blood does not establish greater delivery to cells or better results.
  • But raising blood NAD+ hasn't been shown to improve outcomes — so 'more bioavailable' doesn't mean 'better results.'
  • Oral precursors have multiple randomized human trials confirming they raise NAD+ — and they're the cheapest.
  • Subcutaneous NAD+ has limited human data and no established routine wellness benefit; IV has metabolism and retrospective tolerability pilots, without proven routine wellness benefits.
  • The real deciders are cost and practicality, not bioavailability.
Choosing the most bioavailable route to raise an input that didn't deliver is a more expensive version of the same uncertainty.

Route by route

For a concrete label comparison, the Nuform’s oral and injectable plans separates its oral and injectable kits, upfront supply periods and additional clinical fees. Offering both formats does not establish equivalent absorption, doses or outcomes.

Oral (capsules, powder, sublingual). Oral NR and NMN have a larger randomized human evidence base showing increases in NAD+ 2356. Prices vary by formulation and serving count, and a prescription oral NAD+ offer is not the same substance as an oral precursor: RxSpan MD's flex-dose NAD+ tablet is $199 for the first month, with renewal terms to confirm and Try Ageless sells a compounded NAD+ troche inside a broader longevity menu, while Inner Balance sells a sublingual NAD+ tablet marketed as the needle-free alternative — none of which has the trial base the precursor capsules do, because oral NAD+ itself is not oral NR. If you are pricing the injectable route specifically, note that one provider on this index prices it as a twelve-week block and quotes you the monthly average of it, which is not the same number as a month. The Pepti review covers its current injection offer; it is not evidence for oral capsules or a valid reason to transfer precursor trial findings to another product. Oral NMN and NR are needle-free and can raise blood NAD+, but that does not establish a reliable improvement in how someone feels (see does NMN actually work).

Subcutaneous injection. Sold as a middle ground: more bioavailable than oral, cheaper and more convenient than an IV — roughly $150 to $340 a month across the telehealth providers we track, of which Obu Health's $219 is one of the few that is provably a fixed rate rather than a floor. The top of that band is where the route question turns awkward: Synergy Rx charges $275 a month for its NAD+ shot and charges exactly the same $275 for its glutathione and PT-141 injections — three molecules with three completely different evidence bases at one identical price, which tells you the figure reflects a menu decision rather than anything about what is in the vial. The honest problem is evidence: controlled human trials have not established routine energy, focus or longevity benefits for subcutaneous NAD+, and its human pharmacokinetics remain poorly characterized. We lay this out in what a NAD+ injection is, and what the research shows. Two practical notes for anyone weighing this route: it is usually filed under "peptide therapy" on clinic menus even though NAD+ is not a peptide, and its dosing is expressed in milligrams but drawn in insulin units — a conversion our NAD+ injection dosage calculator handles.

Intravenous infusion. The most expensive and most marketed — $250–$1,500 a session — with no established routine wellness efficacy from the 2019 metabolism pilot or the 2026 retrospective tolerability pilot 19. It also carries the infusion side effects and the ordinary risks of IV access. Full pricing is in how much NAD+ IV therapy costs, and the evidence in our NAD+ IV therapy review.

Intramuscular injection is a separate route. A small hospital trial tested 5 mg/day intramuscular NAD+ as an adjunct for sudden sensorineural hearing loss, with 45 randomized patients and 38 completers. It reported a favorable hearing-threshold change, but used standard care without a matched NAD+ injection as the comparator 10. That finding does not establish a dose or wellness benefit for home subcutaneous shots. See the hearing-loss trial review for the study's limits.

So which is "best"?

If "best" means most proven to raise NAD+ for the least money and hassle, the answer is the unglamorous one: oral precursors. They have the human trial base, they cost a fraction of the alternatives, and they demonstrably raise the biomarker. The injectable and IV routes win the theoretical bioavailability argument but lose the evidence argument — neither has established superior routine wellness outcomes. IV metabolism and short-term tolerability pilots do not answer that comparative benefit question 19.

If "best" means most proven to make me healthier, the honest answer is that no route clears that bar — every route raises (or claims to raise) a biomarker whose elevation hasn't been reliably tied to better outcomes 478. In that light, the practical decision isn't "which route absorbs best" but "how much do I want to spend on an unproven benefit" — so consider whether any intervention is worth its cost and uncertainty before choosing a route. Work through that trade-off in is NAD+ therapy worth it.

The bottom line

Direct delivery does not establish better results, and higher blood NAD+ has not been shown to mean better outcomes 478. Oral precursors have multiple randomized human trials confirming they raise NAD+ 23, they cost the least, and they carry no needle or infusion risk; subcutaneous wellness benefits remain unproven; and the IV route has preliminary metabolism and tolerability data rather than established wellness efficacy 19. Cost and practicality, not bioavailability, are the honest deciders here. Start with our NAD+ therapy evidence pillar, compare precursors in NMN vs NAD+, and see vetted products on our NAD+ rankings hub.

Frequently asked questions

Is IV NAD+ more effective than oral NMN or NR?

There's no evidence it is. IV NAD+ is more bioavailable in theory, but its metabolism and retrospective tolerability pilots do not establish routine wellness benefits or superiority over oral precursors. Oral NMN and NR have human trials showing they reliably raise blood NAD+. Higher bioavailability hasn't been shown to translate into better outcomes.

Does oral NAD+ actually get absorbed?

Oral NAD+ precursors do. Randomized human trials show oral NMN and nicotinamide riboside reliably raise blood NAD+, and multiple studies confirm oral NMN is absorbed and efficiently increases NAD+. The 'oral only absorbs 5–15%' claim is overstated for precursors — whatever the theoretical percentage, they demonstrably hit the biomarker.

Which NAD+ route is best value?

For the narrow goal of raising the blood biomarker, oral precursors have multiple randomized human trials, they cost about $20–$40 a month versus $250–$1,500 per IV session, and they carry no needle or infusion risk. The injectable and IV routes win the theoretical bioavailability argument but have not established routine wellness benefits.

Why doesn't higher bioavailability mean better results for NAD+?

Because raising blood NAD+ is a biomarker, not an outcome. In trials, raising NAD+ via well-absorbed oral routes repeatedly failed to improve muscle performance, cognition, or metabolic parameters. If raising NAD+ itself doesn't reliably help, picking a more bioavailable route to raise it higher solves the wrong problem.

Can the intramuscular hearing-loss trial validate home NAD+ shots?

No. It studied 5 mg intramuscular NAD+ alongside hospital treatment for sudden hearing loss. Route, dose, clinical condition and comparator differ from home subcutaneous wellness use. A favorable finding in that small study does not establish routine energy or longevity benefits.

References

  1. Grant R, Berg J, Mestayer R, et al. (2019). A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. https://pubmed.ncbi.nlm.nih.gov/31572171/
  2. Yi L, Maier AB, Tao R, et al. (2023). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. https://pubmed.ncbi.nlm.nih.gov/36482258/
  3. Martens CR, Denman BA, Mazzo MR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/29599478/
  4. Elhassan YS, Kluckova K, Fletcher RS, et al. (2019). Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Reports. https://pubmed.ncbi.nlm.nih.gov/31412242/
  5. Okabe K, Yaku K, Uchida Y, et al. (2022). Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Frontiers in Nutrition. https://pubmed.ncbi.nlm.nih.gov/35479740/
  6. Irie J, Inagaki E, Fujita M, et al. (2020). Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men. Endocrine Journal. https://pubmed.ncbi.nlm.nih.gov/31685720/
  7. Orr ME, Kotkowski E, Ramirez P, et al. (2024). A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. https://pubmed.ncbi.nlm.nih.gov/37994989/
  8. Oliveira-Cruz A, Macedo-Silva A, Silva-Lima D, et al. (2024). Effects of Supplementation with NAD+ Precursors on Metabolic Syndrome Parameters: A Systematic Review and Meta-Analysis. Hormone and Metabolic Research. https://pubmed.ncbi.nlm.nih.gov/39111741/
  9. Reyna K, Heinzen G, Patel N, et al. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging. https://pubmed.ncbi.nlm.nih.gov/41704678/
  10. Gao M, Guan Y, Yue X, et al. (2026). NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial. The Laryngoscope. https://pubmed.ncbi.nlm.nih.gov/41035311/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.